Kintara Therapeutics (KTRA) Announces 12M Share and Warrant Offering at $1.25/sh

Go back to Kintara Therapeutics (KTRA) Announces 12M Share and Warrant Offering at $1.25/sh

Kintara Therapeutics (KTRA) Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients

September 22, 2021 8:02 AM EDT

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or are resistant to, current treatment regimens today announced topline data results from the newly-diagnosed adjuvant arm of its open-label, Phase 2 clinical study being conducted at the MD Anderson Cancer Center (MD Anderson) in Houston, Texas.

The Phase 2 trial was a two-arm, biomarker-driven study testing... More